<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To verify the spectrum of CD99-expressing lymphoid <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e>, an immunohistochemical study for CD99 was carried out in 182 cases of non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, including 21 lymphoblastic <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, 11 small lymphocytic <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, 9 mantle cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, 12 follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, 37 diffuse large B cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, 18 Burkitt's <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, 28 NK/T-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, 8 angioimmunoblastic T-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, 23 peripheral T-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, unspecified, and 15 systemic anaplastic large cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>CD99 was positive in <z:hpo ids='HP_0000001'>all</z:hpo> T-lymphoblastic <z:hpo ids='HP_0002665'>lymphomas</z:hpo> and in 60% of B-lymphoblastic <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Majority of T and NK cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> were negative for CD99, except anaplastic large cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ALCLs</z:e>) </plain></SENT>
<SENT sid="3" pm="."><plain>Eight of 15 cases (54%) of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ALCLs</z:e> reacted with anti CD99 antibody </plain></SENT>
<SENT sid="4" pm="."><plain>Seven of 10 (70%) ALK positive <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ALCLs</z:e> expressed CD99, whereas only 1 of 5 (20%) ALK negative <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ALCLs</z:e> were positive </plain></SENT>
<SENT sid="5" pm="."><plain>Of the mature B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, 5.4% (2/37) of diffuse large B cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> and 11.1% (2/18) of Burkitt's <z:hpo ids='HP_0002665'>lymphomas</z:hpo> expressed CD99 </plain></SENT>
<SENT sid="6" pm="."><plain>In conclusion, CD99 is infrequently expressed in mature B and T cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, except ALK-positive <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ALCL</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>High expression of CD99 in ALK-positive <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ALCL</z:e> is unexpected finding and its biologic and clinical significances have yet to be clarified </plain></SENT>
</text></document>